journal
MENU ▼
Read by QxMD icon Read
search

European Heart Journal. Cardiovascular Pharmacotherapy

journal
https://www.readbyqxmd.com/read/30192939/mortality-and-adverse-events-with-brand-and-generic-clopidogrel-in-the-food-and-drug-administration-adverse-event-reporting-system-faers
#1
Victor L Serebruany, Trygve S Hall, Dan Atar, Stefan Agewall, Moo Hyun Kim, Bernard Geudelin, Nikita Lomakin, Thomas A Marciniak
Background and Aim: Clopidogrel is commonly used even after expiring patents. The brand clopidogel (BC) was dealt by single company, while numerous manufacturers produce generic clopidogrel (GC). There are no convincing data to compare the safety of different formulations. Therefore, the data yielded from international, uniform, government-mandated registries may be useful. Methods and Results: We assessed primary causative adverse events (PCAE) after BC and GC in the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS)...
September 6, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30192930/effect-of-oral-%C3%AE-blocker-treatment-on-mortality-in-contemporary-post-myocardial-infarction-patients
#2
Magnus Dahl Aarvik, Irene Sandven, Tatendashe B Dondo, Chris P Gale, Vidar Ruddox, John Munkhaugen, Dan Atar, Jan Erik Otterstad
Aims: Guidelines concerning β-blocker treatment following acute myocardial infarction (AMI) are based on studies undertaken before the implementation of reperfusion and secondary prevention therapies. We aimed to estimate the effect of oral β-blockers on mortality in contemporary post-AMI patients with low prevalence of heart failure (HF) and/or reduced left ventricular ejection fraction (LVEF). Methods and Results: A random effects model was used to synthetize results of 16 observational studies published between January 1st 2000 and October 30th 2017...
September 6, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30165588/esc-council-on-hypertension-position-document-on-the-management-of-hypertensive-emergencies
#3
Bert-Jan H van den Born, Gregory Y H Lip, Jana Brguljan-Hitij, Antoine Cremer, Julian Segura, Enrique Morales, Felix Mahfoud, Fouad Amraoui, Alexandre Persu, Thomas Kahan, Enrico Agabiti Rosei, Giovanni de Simone, Philippe Gosse, Bryan Williams
Hypertensive emergencies are those situations where very high blood pressure (BP) values are associated with acute organ damage, and therefore, require immediate, but careful, BP reduction. The type of acute organ damage is the principal determinant of: (i) the drug of choice, (ii) the target BP, and (iii) the timeframe in which BP should be lowered. Key target organs are the heart, retina, brain, kidneys, and large arteries. Patients who lack acute hypertension-mediated end organ damage do not have a hypertensive emergency and can usually be treated with oral BP-lowering agents and usually discharged after a brief period of observation...
August 25, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30101278/influence-of-intravenous-fentanyl-compared-with-morphine-on-ticagrelor-absorption-and-platelet-inhibition-in-patients-with-st-segment-elevation-myocardial-infarction-undergoing-primary-percutaneous-coronary-intervention-rationale-and-design-of-the-perseus-randomized
#4
Sophie Degrauwe, Marco Roffi, Nathalie Lauriers, Olivier Muller, Pier Giorgio Masci, Marco Valgimigli, Juan F Iglesias
Background and aims: Recent evidence demonstrates that intravenous morphine significantly reduces absorption and delays onset of action of oral P2Y12 receptor inhibitors in patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI). We aimed to assess the influence of intravenous fentanyl compared with morphine on pharmacokinetics (PK) and pharmacodynamics (PD) of ticagrelor and its active metabolite (AR-C124910XX) in patients undergoing pPCI for STEMI...
August 8, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30099530/reasons-for-disparity-in-statin-adherence-rates-between-clinical-trials-and-real-world-observations-a-review
#5
Alexander Vonbank, Heinz Drexel, Stefan Agewall, Basil S Lewis, Joern F Dopheide, Keld Kjeldsen, Claudio Ceconi, Gianluigi Savarese, Giuseppe Rosano, Sven Wassmann, Alexander Niessner, Thomas Andersen Schmidt, Christoph H Saely, Iris Baumgartner, Juan Tamargo
With statins, the reported rate of adverse events differs widely between randomized clinical trials (RCTs) and observations in clinical practice, the rates being 1-2% in RCTs versus 10-20% in the so-called real world. One possible explanation is the claim that RCTs mostly use a run-in period with a statin. This would exclude intolerant patients from being included into RCTs and therefore favor a bias towards lower rates of intolerance.We here review data from RCTs with more than 1000 participants with and without a run-in period, which were included in the Cholesterol Treatment Trialists collaboration (CTTC)...
August 7, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30113628/critical-appraisal-of-the-compass-trial
#6
Alexander Niessner, Stefan Agewall
No abstract text is available yet for this article.
August 2, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30084902/trends-in-cardiovascular-and-bleeding-outcomes-in-acute-coronary-syndrome-patients-treated-with-or-without-proton-pump-inhibitors-during-the-introduction-of-novel-p2y12-inhibitors-a-five-year-experience-from-a-single-centre-observational-registry
#7
N P G Hoedemaker, P Damman, J P Ottervanger, J H E Dambrink, A T M Gosselink, E Kedhi, E Kolkman, R J de Winter, A W J van 't Hof
Objective: Proton-pump inhibitors (PPI) are commonly prescribed in acute coronary syndrome (ACS) patients on antiplatelet therapy. We studied PPI prescription in ACS patients in the era of novel P2Y12 inhibitors and assessed the association between PPI use and clinical outcomes. Methods: Between 2010 and 2014, we included all consecutive ACS patients admitted to a Dutch tertiary hospital. The main outcome was PPI prescription at discharge. Additionally, we present 1-year mortality and 30-day cardiovascular and bleeding outcomes...
August 2, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30084983/head-to-head-comparison-between-the-non-vitamin-k-antagonist-oral-anticoagulants-for-treatment-of-venous-thrombo-embolism-do-we-really-need-it
#8
Dragos Vinereanu
No abstract text is available yet for this article.
July 31, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30060063/development-of-triglyceride-lowering-drugs-to-address-residual-cardiovascular-risk-strategic-and-clinical-considerations
#9
Jonas Hallén, Nadarajah Sreeharan
The prevalence of hypertriglyceridemia is high and growing in several parts of the world. Hypertriglyceridemia has a well-defined association with the risk of atherosclerotic cardiovascular (CV) disease and thus represents a potential target for drugs aimed at mitigating CV events. So far, no triglyceride-lowering pharmacological strategy has succeeded in conclusively showing the ability to modify clinical outcomes. This article discusses strategic and clinical aspects of development of triglyceride-lowering drugs to address CV disease...
July 27, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30052825/a-randomized-double-blind-placebo-controlled-trial-assessing-the-efficacy-of-s66913-in-patients-with-paroxysmal-atrial-fibrillation
#10
John A Camm, Paul Dorian, Stefan H Hohnloser, Peter R Kowey, Benoît Tyl, Yongbin Ni, Victoria Vandzhura, Pierre Maison-Blanche, Mirko de Mellis, Prashanthan Sanders
Background: Anti-arrhythmic drugs (AAD) for the treatment of atrial fibrillation (AF) are associated with limited efficacy and adverse effects. Inhibition of the atrial current IKur, absent from the ventricle, is expected to be antiarrhythmic, without adverse cardiac effects, particularly ventricular pro-arrhythmic effects. Methods: A randomized clinical trial in symptomatic paroxysmal AF patients being considered for ablation. The primary endpoint was AF burden (AFB) as measured by insertable continuous monitoring (ICM) devices...
July 23, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30052822/differences-in-the-risk-of-stroke-bleeding-events-and-mortality-between-female-and-male-patients-with-atrial-fibrillation-during-warfarin-therapy
#11
Tero Penttilä, Mika Lehto, Jussi Niiranen, Juha Mehtälä, Houssem Khanfir, Riitta Lassila, Pekka Raatikainen
Aims: Females with atrial fibrillation (AF) have been suggested to carry a higher risk for thromboembolic events than males. We compared the residual risk of stroke, bleeding events, and cardiovascular and all-cause mortality among female and male AF patients taking warfarin. Methods and results: Data from several nationwide registries and laboratory databases were linked with the civil registration number of the patients. A total of 54568 patients with data on the quality of warfarin treatment (time in therapeutic range) 60 days prior to the events were included (TTR60)...
July 21, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30020424/effectiveness-and-safety-of-rivaroxaban-versus-warfarin-in-nonvalvular-atrial-fibrillation-patients-with-a-non-sex-related-cha2ds2-vasc-score-of-1
#12
Craig I Coleman, Alexander G G Turpie, Thomas J Bunz, Daniel Eriksson, Nitesh A Sood, William L Baker
Aims: To compare the effectiveness and safety of standard dose rivaroxaban (20 mg once daily) and warfarin in nonvalvular atrial fibrillation (NVAF) patients with a non-sex-related CHA2DS2-VASc score of 1. Methods and Results: Analysis of United States Truven MarketScan claims from 11/2011-12/2016 for anticoagulant-naïve NVAF patients with a single non-sex-related stroke risk factor assigned 1-point in the CHA2DS2-VASc score and ≥12-months of continuous medical/prescription insurance coverage prior to the qualifying oral anticoagulant dispensing...
July 17, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/29982385/new-potassium-binders-reduce-the-risk-of-hyperkalaemia-in-patients-treated-with-renin-angiotensin-aldosterone-system-inhibitors
#13
Maria Tamargo, Juan Tamargo
No abstract text is available yet for this article.
July 2, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/29945162/safety-and-effectiveness-of-rivaroxaban-and-apixaban-in-patients-with-venous-thromboembolism-a-nationwide-study
#14
Caroline Sindet-Pedersen, Laila Staerk, Jannik Langtved Pallisgaard, Thomas Alexander Gerds, Jeffrey S Berger, Christian Torp-Pedersen, Gunnar H Gislason, Jonas Bjerring Olesen
Aim: To investigate the risk of all-cause mortality, recurrent VTE, and hospitalized bleeding in patients with VTE treated with either rivaroxaban or apixaban. Methods and results: Using Danish nationwide registries, patients with VTE treated with rivaroxaban or apixaban in the period from January 1st 2015 to June 30th 2017 were identified. Standardized absolute risks were estimated based on outcome-specific Cox regression models, adjusted for potential confounders...
June 26, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30052852/new-input-on-antiplatelet-treatment-and-registry-studies
#15
Stefan Agewall
No abstract text is available yet for this article.
July 1, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30052851/peripheral-arterial-disease-and-limb-salvage-a-new-arena-for-the-cardiologist
#16
Basil S Lewis, Dan Atar
No abstract text is available yet for this article.
July 1, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30052850/esc-2017-stemi-guidelines-a-step-forward-for-a-better-cure
#17
Marco Tubaro
No abstract text is available yet for this article.
July 1, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/30052849/2017-esc-guidelines-focus-on-dual-antiplatelet-therapy
#18
Giuseppe M C Rosano, Petar Seferovic
No abstract text is available yet for this article.
July 1, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/29726985/expert-consensus-document-on-the-management-of-hyperkalaemia-in-patients-with-cardiovascular-disease-treated-with-renin-angiotensin-aldosterone-system-inhibitors-coordinated-by-the-working-group-on-cardiovascular-pharmacotherapy-of-the-european-society-of-cardiology
#19
Giuseppe M C Rosano, Juan Tamargo, Keld P Kjeldsen, Mitja Lainscak, Stefan Agewall, Stefan D Anker, Claudio Ceconi, Andrew J S Coats, Heinz Drexel, Gerasimos Filippatos, Juan Carlos Kaski, Lars Lund, Alexander Niessner, Piotr Ponikowski, Gianluigi Savarese, Thomas A Schmidt, Petar Seferovic, Sven Wassmann, Thomas Walther, Basil S Lewis
Renin angiotensin aldosterone system inhibitors/antagonists/blockers (RAASi) are a cornerstone in treatment of patients with cardiovascular diseases especially in those with heart failure (HF) due to their proven effect on surrogate and hard endpoints. Renin angiotensin aldosterone system inhibitors are also the basis in treatment of arterial hypertension, and they are furthermore indicated to reduce events and target organ damage in patients with diabetes and chronic kidney disease, where they have specific indication because of the evidence of benefit...
July 1, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
https://www.readbyqxmd.com/read/29562254/corrigendum-to-annual-adverse-event-profiles-after-clopidogrel-prasugrel-and-ticagrelor-in-the-food-and-drug-administration-adverse-event-reporting-system
#20
(no author information available yet)
No abstract text is available yet for this article.
July 1, 2018: European Heart Journal. Cardiovascular Pharmacotherapy
journal
journal
53372
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"